You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表現》微泰醫療(02235.HK)高開1.6%報31元
微泰醫療-B(02235.HK)暗盤低開5.9%報28.7元,高低見31.3元/27.8元,收30.9元,較上市價反覆高1.3%;該股首掛開報31元,較上市價30.5元,高1.6%,市前成交108萬股。 微泰在2011年成立,總部位於杭州,是仍未有盈利、主要提供糖尿病治療及糖尿病監測醫療器械的生物科技企業,目前公司收入增長主要由核心產品Equil貼敷式胰島素泵系統的銷售帶動。是次上市共發售約6,353萬股H股,並引入包括景順、UBS AM Singapore及騰訊(00700.HK)全資附屬Tencent Mobility等11家基石投資者,合共認購3,917.13萬股H股;其中10%公開發售獲5.8倍超購,認購一手中籤率80%;股份以接近招股範圍(27.7-31.15元)上限定價,料集資淨額約18.15億元,主要用作公司核心產品、持續血糖監測系統、第二代貼敷式胰島素泵,以及其他產品與在研產品的臨牀前研究、臨牀試驗、註冊、生產及商業化等。上市聯席保薦人分別爲高盛及中金。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account